Pipeline

Therapies that Target the INNATE IMMUNE Response

 

DN-TNF PlatformDisease FieldPre-clinicalPhase IPhase II (POC)PivotalEst. Next Milestone
Mild Alzheimer’s Disease CNS
XPRO™
Mild AD
      P2 Start Q4-2021
MCI
XPRO™
Mild Cognitive Impairment
      P2 Start 1H-2022
Treatment Resistant Depression
XPRO™
NIH logo
Treatment
Resistant Depression
      P2 Start 1H-2022

INB03 for treatment of MUC4 positive cancer and LIVNate for NASH Phase II trials begin after resolution of pandemic

NK-Priming PlatformDisease FieldPre-clinicalPhase IPhase II (POC)PivotalEst. Next Milestone
Inmune Bio for High-Risk MDS
INKmune™
Myelodysplastic Syndrome
ONCOLOGY
      P1 Underway
Inmune Bio for High-Risk MDS
INKmune™
Ovarian Cancer
      P1 Start 1H - 2022

INKmune for treatment of ovarian cancer Phase I trial begins after resolutions of pandemic

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST